Loading...
XNAS
VRAX
Market cap2mUSD
Dec 05, Last price  
0.63USD
1D
-2.24%
1Q
11.43%
IPO
-99.65%
Name

Virax Biolabs Group Ltd

Chart & Performance

D1W1MN
XNAS:VRAX chart
P/E
P/S
431.80
EPS
Div Yield, %
Shrs. gr., 5y
22.23%
Rev. gr., 5y
-42.40%
Revenues
6k
-95.95%
99,876123,82000156,4196,331
Net income
-6m
L-9.98%
-801,131-650,984-1,708,827-5,457,494-6,733,537-6,061,247
CFO
-5m
L-26.95%
-744,613-590,186-809,069-4,179,767-6,247,016-4,563,576

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.
IPO date
Jul 14, 2022
Employees
11
Domiciled in
GB
Incorporated in
KY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT